Advertisement

Annals of Hematology

, Volume 87, Issue 9, pp 763–765 | Cite as

JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia

  • María J. Moreno
  • María L. Lozano
  • V. Roldán
  • B. Bellosillo
  • N. García-Barberá
  • J. Rivera
  • L. Navarro-Núñez
  • C. Besses
  • V. Vicente
  • C. Martínez
Letter to the Editor

Dear Editor,

A recent mutation located in the JAK2 gene, JAK2 V617F, has been shown to play a transcendental role in the constitutive activation of its tyrosine kinase activity in an important number of cases of Philadelphia negative myeloproliferative disorders (Ph-MPDs). This mutation is a useful tool for diagnosing this diseases because different studies show that this mutation is highly frequent in patients with polycythemia vera (PV) and is present in around 50% of the patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) [1]. Among the clinical features and phenotypes that characterize Ph-MPD patients, thrombotic and hemorrhagic episodes have been shown to be frequent in these patients. Range values for thrombosis at diagnosis fluctuate between 34% to 39% for PV and 10% to 29% for ET [2]. For hemorrhage, the values are much more variable [3].

The mechanisms accounting for the increased risk of thrombosis and hemorrhage in Ph-MPD patients are not well...

Keywords

Thrombotic Event Polycythemia Vera Thrombophilia Arterial Thrombosis Essential Thrombocythemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Campbell PJ, Green AR (2006) The myeloproliferative disorders. N. Engl J Med 355:2652–2666CrossRefGoogle Scholar
  2. 2.
    Tefferi A, Elliott MA (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Haemost 33:313–320CrossRefGoogle Scholar
  3. 3.
    Elliott MA, Tefferi A (2005) Thrombosis and Haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275–290PubMedCrossRefGoogle Scholar
  4. 4.
    Griesshammer M (2006) Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 32:372–380PubMedCrossRefGoogle Scholar
  5. 5.
    Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109:2310–2313PubMedCrossRefGoogle Scholar
  6. 6.
    Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, Pruthi RK, Tefferi A (2004) Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 15:21–24PubMedCrossRefGoogle Scholar
  7. 7.
    Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 71:1–6PubMedCrossRefGoogle Scholar
  8. 8.
    Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 132:244–245PubMedCrossRefGoogle Scholar
  9. 9.
    Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846PubMedCrossRefGoogle Scholar
  10. 10.
    Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13:150–154PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • María J. Moreno
    • 1
  • María L. Lozano
    • 1
  • V. Roldán
    • 1
  • B. Bellosillo
    • 2
  • N. García-Barberá
    • 1
  • J. Rivera
    • 1
  • L. Navarro-Núñez
    • 1
  • C. Besses
    • 2
  • V. Vicente
    • 1
  • C. Martínez
    • 1
  1. 1.University of Murcia, Centro Regional de HemodonaciónMurciaSpain
  2. 2.Hospital del MarIMASBarcelonaSpain

Personalised recommendations